Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination

There is a limited supply of COVID-19 vaccines, with less than 20% of eligible populations in low-income countries having received one dose. Intradermal delivery of fractional dose vaccines is one way to improve global vaccine access, but no studies have reported data on intradermal delivery of COVI...

Full description

Bibliographic Details
Main Authors: Somruedee Chatsiricharoenkul, Suvimol Niyomnaitham, Harry Joshua Posen, Zheng Quan Toh, Paul V. Licciardi, Patimaporn Wongprompitak, Thaneeya Duangchinda, Pattarakul Pakchotanon, Warangkana Chantima, Kulkanya Chokephaibulkit
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
COVID vaccine
fractional dose vaccination
heterologous regimen
intradermal vaccine
vaccine immunogenicity
vaccine safety
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1010835/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1010835/full

Similar Items